. The rapid development of deep-sequencing and computational technologies has provided great opportunities to explore the structure and functionality of the microbial communities that are associated with our body surfaces. Extensive microbial data generated worldwide have enabled the scientific community to uncover the functions of the human microbiota 12 . Bacterial communities have been the primary focus of these sequencing efforts, and fewer data are currently available that characterize the fungal microbiota -the mycobiota. Nevertheless, recent studies have revealed that host-associated fungal populations are also dynamic and responsive to environmental and pathophysiological changes 9, [13] [14] [15] [16] [17] .
A century of studies that focused on commensal bacteria in the gut have suggested that dysbiosis 18 is at the root of several diseases of complex aetiology and that involve genetic polymorphisms, immune mechanisms and the microbiota [19] [20] [21] . Although the term dysbiosis is imperfect, it describes conditions that are distinct from infection and it is widely used to describe altered bacterial communities as both a cause and a consequence of pathologies (BOX 2) . Nevertheless, infection and dysbiosis can both prelude each other -either homeostasis can be followed by dysbiosis and then infection, or homeostasis can be followed by infection and then lead to dysbiosis -in a dynamic continuum. Several studies have indicated that a similar process involving fungal communities -fungal dysbiosis -could affect the host mycobiota 9, 16, 17, [21] [22] [23] [24] (FIG. 1) . As fungi are common inhabitants of all barrier surfaces, changes in fungal communities might have substantial effects on the host immune responses.
In this Review, we discuss the mycobiota in homeo stasis and dysbiosis, how mucosal immunity distinguishes between fungal infections and fungal dysbiosis, and how mucosal immunity responds to these conditions. We define the specific mycobiota patterns that are associated with fungal dysbiosis and changes in mycobiota diversity at several body sites. Finally, we discuss the impact of fungal dysbiosis on Internal transcribed spacer (ITS) . A sequence in the fungal genome positioned between the 18S and 5.8S (ITS1) or the 5.8S and 28S (ITS2) fungal rDNA that is widely used in mycobiome next-generation sequencing. The variability of the ITS regions enables them to be used to classify fungal genera and species.
Operational taxonomic units (OTUs) . Clusters of marker gene sequences (for example, 16S rRNA or internal transcribed spacer) based on sequence similarity used for taxonomy-independent community analysis.
commensal bacteria and how these two fundamentally different communities influence each other to affect the outcome of the immune response.
Mycobiota at steady state and in dysbiosis Fungi have traditionally been studied using culture-dependent methods. Only recently have advances in deep-sequencing technologies provided opportunities to unveil the complexity of the fungal communities that colonize mammalian barrier surfaces. Most approaches have relied on sequencing the fungal internal transcribed spacer (ITS) ITS1 and ITS2 regions and using computational algorithms to align operational taxonomic units (OTUs) to respective fungal databases 9, 16, 25, 26 . Whereas fungal identification remains challenging in environmental and soil samples owing to enormous fungal diversity and the presence of many unknown fungal species 27 , the development of several databases designed to specifically target host-associated fungal communities has made it possible to identify more than 80% of the fungal ITS sequences derived from faecal or mucosal samples 9, [28] [29] [30] . Despite this progress, each step of this identification approach can contribute to biases 26, 28 and can complicate the comparison of mycobiota sequencing results from different studies. Additional bias might be introduced by therapeutic and dietary interventions that can contribute to further changes in fungal communities 15 . Despite these confounding factors, several studies have revealed similarities in how fungal communities adapt to environmental perturbations, and these are summarized below. Keeping in mind the limitations that the term dysbiosis imposes
, we further define the specific conditions that are associated with fungal community disruption in the context of inflammatory diseases, host immunity and drug-triggered microbial alterations.
Mycobiota in the oral cavity
The oral cavity is one of the first mucosal sites where the asymptomatic carriage of fungi was described 31 . Diversity in the oral mycobiota is low and it is dominated by members of the Ascomycota phylum, mainly Candida spp. 25, 32 . Culture-independent methods have revealed that most fungal species in the oral cavity are Fusarium spp. or members of a species belonging to the Saccharomycetaceae family (such as Candida albicans, Candida dubliniensis, Candida rugosa, Candida pararugosa, Saccharomyces cerevisiae, Hanseniaspora uvarum and Pichia spp.) 25, 32 . Dysbiosis in the oral mucosa is poorly characterized and most studies have focused on the overgrowth of C. albicans upon immuno suppression and diabetes 32 (FIG. 1b) . The first culture-independent assessment of the oral mycobiota in patients with HIV revealed that, in addition to the overgrowth of C. albicans, the presence of other species belonging to the Ascomycota phylum, including Dothideomycetes spp. and Leotiomycetes spp., was also increased, whereas the presence of Tremellomycetes spp. was reduced 32 . Of note, this study did not observe any alteration in the bacterial microbiota, indicating that the observed fungal dysbiosis was probably mediated by a direct effect of the compromised immune system and not by an indirect effect mediated by changes in the bacterial microbiota.
Mycobiota in the gastrointestinal tract
The fungal community in the lower gastrointestinal tract has higher richness and is more diverse than that in the upper gastrointestinal tract. A recent review of 36 published gut mycobiota articles concluded that only 15 of the 267 identified species were detected in more than 5 studies 33 . Among these 15 species, 13 can grow at 37 o C and thus have the potential to permanently inhabit the intestinal niche 22, 34 . These species belong to the genera Candida, Saccharomyces, Aspergillus, Cryptococcus, Malassezia, Cladosporium, Galactomyces and Trichosporon
33
. Nevertheless, commensalism is not the only way in which fungi can influence host immunity. For example, although Histoplasma spp., Blastomyces spp. and Coccidioides spp. cannot colonize the mucosal surfaces, they can cause severe infections in the lung 35 . Similarly, non-commensal fungi that are present in the diet, the air or other environmental sources, might also activate immune responses in the gut 15, 24 (FIG. 1b) .
The high fungal variability observed in different studies has been interpreted as a sign of the temporal instability of the intestinal mycobiota 13, 34 . However, most of these studies relied on the sampling of faecal material. Although additional data are needed to draw definitive conclusions, a recent study of mucosa-associated fungi suggests that a more stable community is associated with the gut mucosa 36 and that this can be perturbed during intestinal disease 37 . These results are interesting, as fungi that are in close proximity to the intestinal mucosa might
Box 1 | Ecological relationships between fungi and their hosts
There are numerous examples of oppositional and symbiotic relationships between fungi and animals. Whereas some fungi, such as members of the Pleurotaceae family, have become predators and use elaborate strategies to catch and to digest nematodes that live in the soil, other fungi, such as Harposporium spp. and Ophiocordyceps spp., have adapted to a parasitic lifestyle 128 . Ophiocordyceps spp. have gone as far as manipulating host behaviour to ensure their own survival and dispersal 128 . Other fungi, such as Blastomyces dermatitidis and some Aspergillus species, have developed mechanisms that mimic mammalian regulatory molecules and suppress host immunity 129, 130 . The skin and the mucosal surfaces of animals and humans are rich in nutrients and provide temperate environments for commensal fungal symbionts to thrive. Malassezia spp. are well adapted to sebaceous microenvironments and are abundantly present on the skin 9, 60 . The feet are home to a diverse fungal community that is dominated by saprophytic fungi that feed on dead cells, which are shed continuously at this skin site 9 . Symbiotic relationships between fungi and their hosts are well established in the gastrointestinal tracts of different orders of animals, from insects to mammals 10, 11 . Whereas some fungal symbionts are crucial for processing indigestible lignocellulose, which is associated with a herbivorous diet, other symbionts produce enzymes that are necessary for the neutralization of toxic dietary compounds 11 . The host, conversely, provides the commensal mycobiota with an optimal environment to grow, feed and procreate. In some cases, the fungal symbionts are even vertically transmitted through generations 131 , suggesting that, similar to bacterial symbiosis, some fungal commensals might be inherited from the mother. Recently, high-throughput sequencing approaches revealed that mouse and human intestines are home to a diverse fungal community that might have an important role in host physiology and immunity 13, [15] [16] [17] 21 .
Richness
The number of different species represented in an ecological community.
Commensalism
A relationship between two species through which one organism benefits from the other without affecting it.
Inflammatory bowel disease have an increased potential to interact locally with the intestinal epithelium and the mucosal immune system. It has been known for a long time that inflammatory conditions that target the lower gastrointestinal tract can promote bacterial dysbiosis, and this has highlighted the important contribution of bacteria to the aetiology of inflammatory bowel disease (IBD) 38, 39 . In light of these findings, several studies have investigated fungal dys biosis in patients with IBD and have identified a general increase in the fungal burden in the colonic mucosa during both Crohn's disease 21, 22 and ulcerative colitis 40 . Consistent with these results, increases in fungal burden and pronounced fungal translocation occur in the mucosa during the chronic stage of colitis 41 , as well as during the acute stage of colitis in mice deficient in Clec7a (which encodes the fungal receptor dectin 1 (see below)) 16 . Together, these studies suggest that genetic factors, extensive tissue damage and the presence of an inflammatory environment can cause fungal dysbiosis in the gut.
Several fungal taxa seem to be consistently altered during chronic intestinal inflammation. Patients with IBD have an increased occurrence and abundance of cultivable C. albicans in the faeces, and this has been further confirmed by culture-independent studies 17, [21] [22] [23] . In patients with Crohn's disease, the presence of C. albicans and Candida parapsilosis increased in the inflamed mucosa 37 . Increased abundance of Candida tropicalis in Crohn's disease correlated with inflammation and increased levels of anti-S. cerevisiae antibody (ASCA) 23 . Consistently, intestinal inflammation is sufficient to promote Candida spp. colonization and increased abundance in the mouse gut 16, 41 . Although it is clear that Candida spp. increase during intestinal disease (FIG. 1a) , the effect of the expansion on other gut fungi remains unclear. Some studies have suggested that the presence of species of the phylum Ascomycota decreases in favour of an increase in species of the phylum Basidiomycota 17, 37 , whereas another study reported a general increase in five species of the phylum Ascomycota in IBD 21 . Clone library approaches based on 18S rDNA denaturing gradient gel electrophoresis (DGGE) show that patients with Crohn's disease have increased fungal diversity and richness in the faeces and the mucosa, compared with healthy individuals and with individuals who have other forms of intestinal inflammation, such as patients with infectious colitis 37, 40 . By contrast, ITS-sequencing approaches showed either no changes in the mycobiota diversity in faecal samples 17 and colonic mucosa 22 during Crohn's disease, or a reduction in fungal diversity in a paediatric IBD cohort that mainly included patients with Crohn's disease 42 . A further study showed decreased species richness in the faeces of patients with Crohn's disease and their healthy relatives compared with unrelated healthy controls, but no change in fungal diversity was reported 23 . Interestingly, one study showed that patients with active ulcerative colitis have a clear reduction in fungal diversity 17 . The differences in the gut mycobiota observed among different studies suggest that, in addition to inflammation, other factors, such as immunosuppressive therapy, disease type (Crohn's disease or ulcerative colitis) and disease-specific diet might influence the structure of the mycobiota in patients with IBD.
Patients with Crohn's disease have increased levels of antifungal antibodies, which show that an immune response to intestinal fungi is elicited during IBD 43 . These systemic IgG and IgA ASCA immunoglobulins are widely recognized as reliable diagnostic markers for Crohn's disease and are good predictors of the disease course 43 . Recent studies have shown that C. albicans can act as an immunogen for ASCA production 44 and that ASCAs cross-react with cell wall mannans isolated from other yeasts, including commensal Candida species 45 . Despite this link with intestinal fungi, the exact mechanism behind ASCA generation and the role of ASCAs in antifungal immunity are not yet understood.
The frequent co-occurrence of gastrointestinal symptoms and neurodevelopmental disorders has uncovered the presence of bacterial dysbiosis in autism-spectrum disorders (ASDs), schizophrenia and other neurodevelopmental disorders 46, 47 . Patients with ASD and Rett syndrome were recently reported to have altered intestinal mycobiota 47, 48 ; however, whether fungi also contribute to the development of gastrointestinal symptoms in these patient groups is currently unknown.
Mycobiota in the lung, vagina and skin
Disease-mediated fungal dysbiosis has been described at other barrier sites that have a lower fungal burden than the gut. The healthy lung has long been considered an aseptic organ and bacterial colonization was thought to occur only during disease 20 . Similarly, the fungal burden is generally low in healthy individuals whose lung mycobiota seems to mostly comprise environmental fungi or fungi disseminating from the oral cavity,
Box 2 | Uncoupling infection from dysbiosis
Early in the 16th century, Girolamo Fracastoro proposed that minute invisible seedsseminaria -transmit diseases from person to person 132 . This revolutionary theory of the microbial origin of disease was proven approximately 100 years later with the development of the microscope by Antony van Leeuwenhoek 133 . It took another 200 years for the theory to fully ripen. In the second half of the 19th century, Louis Pasteur and Friedrich Jakob Henle independently published their ideas of the microbial origin of diseases 134, 135 . The idea was further developed by Robert Koch 112 , who eventually developed guidelines known as Koch's postulates that were intended to move the field forwards from observations to evidence-based causative relationships between microorganisms and disease 136 . Over the years, Koch's postulates have undergone several modifications to incorporate acute and chronic diseases with diverse aetiologies 137 and to include advances led by genomics-based approaches in clinical microbiology and virology 138, 139 . Although Koch's postulates framed the idea of the microbial origin of infectious diseases, they cannot explain situations in which microorganisms indirectly shape a pro-inflammatory or an anti-inflammatory environment to affect immunity. During the second half of the 19th century, while working on causes of longevity, Ilya Ilyich Metchnikov theorized that intestinal microorganisms can "auto-intoxicate and auto-infect" their host 18 . Metchnikov and colleagues Stamen Grigorov and Léon Massol proposed that lactic acid-producing bacteria, which they called Bulgarian bacillus, can decelerate this process 18 . Together with the concept of beneficial bacteria, Metchnikov coined the term dysbiosis (initially known as dysbacteriosis) to define the pathological changes of the intestinal microflora 18 . However, dysbiosis is a general and wide definition, which can be applied to either cause or effect. Some have criticized these shortcomings 140 or have attempted to define dysbiosis within several conditions 141 . Similar to the modifications that Koch's postulates underwent over time, the concept of dysbiosis will probably evolve to reflect the modern advances in microbiome science. including species belonging to the genera Cladosporium, Aspergillus, Penicillium and Candida 25, 32, 49 . By contrast, more stable fungal communities can colonize the lung when its physiology is altered (FIG. 1b) . In most patients with cystic fibrosis, for example, the fungal burden in the lung seems to be increased, whereas alpha diversity is reduced and this is correlated with disease severity 50, 51 . Despite the high inter-individual variability of mycobiota composition, fungal genera such as Candida and Aspergillus have been linked to morbidity in individuals with cystic fibrosis 50, 51 . Of note, once established, lung dysbiotic fungal communities seem to stabilize and persist even in the presence of antibiotic therapy or immunosuppressant therapy 51, 52 . Fungi have also been linked to the severity of asthma 20, 53 ; however, it is unclear whether the effect is local or is influenced by the intestinal mycobiota, as suggested by experimental studies 24, 54, 55 .
Vaginal candidiasis is one of the most common mucosal fungal infections in humans. However, fungal communities are present in healthy women without active infections. Similar to the oral mucosa and mycobiota, the vaginal myco biota has low diversity and the vaginal mucosa is mainly colonized by C. albicans, Candida glabrata, Candida krusei, C. parapsilosis and S. cerevisiae [56] [57] [58] . Several factors, such as antibiotic use, pregnancy, HIV infection and recurrent vulvovaginal candidiasis, have been associated with alterations of the vaginal fungal community structure 56, 58, 59 ( FIG. 1b) . Candida spp. colonization of the vagina increases by up to 40% during pregnancy, owing to increased oestrogen levels in and glycogen production by vaginal epithelial cells, and this might have important consequences for pregnant women, including preterm delivery 56 . In contrast to the other surfaces of the body, the skin is cold, dry and has a higher availability of lipids and , lung 53 , skin 9 , gut 14, 17, 22 and vagina 57 (left side). The pie charts represent the relative abundance of the observed taxa at the phylum and genus levels (inner and outer circles, respectively). Of note, the data for the vagina are estimates that are based on culture-dependent studies, due to a lack of sequencing-based studies related to disease conditions (indicated with an asterisk). 'Other' refers to sequences with <5% relative abundance. During disease states, these fungal communities are perturbed (right side). Dysbiotic fungal communities are observed in the oral cavity 32 and the vagina 58 in individuals with HIV; in the lungs of individuals with cystic fibrosis 51 ; on the skin of individuals with primary immunodeficiency 61 and chronic wounds 63 ; and in the gut of patients with Crohn's disease 14, 17, 22 . b | Factors contributing to fungal dysbiosis at different barrier surfaces. AF, antecubital fossa; HF, hind foot; STAT3, signal transducer and activator of transcription 3.
proteins (such as keratin), which constitute the major nutrients for the colonizing fungal flora, including lipophilic species such as Propionibacterium spp. and Malassezia spp. 9, 60 . The skin microbiota shows temporal stability and can be influenced by primary immunodeficiencies [60] [61] [62] . When skin integrity is compromised, fungi rapidly populate the wound site. A recent study demonstrated that fungi are present in 80% of chronic wounds in patients with type 1 or type 2 diabetes 63 (FIG. 1b) . Despite the high interpersonal variability of the wound mycobiota, this study showed an association of Candida spp., Trichosporon spp. and Rhodotorula spp. with non-healing wounds and amputation, and temporally unstable fungal and bacterial communities were associated with a positive healing outcome 63 . Therefore, in addition to bacteria, the specific signature of a wound fungal community can have a negative outcome on the skin-healing process.
Together, these studies suggest that disease-induced dysbiotic fungal communities are often well adapted to changes that are induced by pathological conditions and can contribute to the disease course. Further studies are required in treatment-naive individuals, including paediatric patients and newly diagnosed patients, to provide crucial insights into a purely disease-driven dysbiosis. Mouse studies are an essential tool to analyse the effect of fungal dysbiosis under such conditions and have already provided some evidence for fungal involvement in several pathologies (discussed below).
Influence of age, gender, diet and environment
Several studies have shown a high variability of the mycobiota between different individuals, which complicates the distinction between healthy and dysbiotic fungal communities. This variability highlights the need for a stricter definition of dysbiosis (BOX 2) and the need for experimental studies that define the consequences of an altered mycobiota. For example, the composition of the mycobiota in the gastrointestinal tract is influenced substantially by diet, gender, age and geographical location 64 . Aspergillus spp. and Tremellomycetes spp. are more abundant in male individuals, whereas Candida spp. are more abundant in females, possibly owing to these fungi spreading from the vagina 64 . Genera such as Aspergillus, Tremellomycetes and Penicillium are abundant in infants, whereas the overall diversity of the fungal community decreases with age 42, 64 . Similarly, the diversity of the skin mycobiota decreases with age, probably owing to increasingly sebaceous skin that favours colonization by Malassezia species 65 . Diet can influence not only bacterial but also fungal communities, as food is a constant source of fungal species that are associated with vegetables, fruits and dairy products 15 . Individuals who ate a controlled animal-derived diet that was rich in cheese had an increased fungal burden in the gut, and fungal species that were detected in the faeces of these individuals corresponded to those isolated from the food that they had consumed 15, 34 . Diet might be one of the factors that contributes to the differences in the fungal community that are observed between different ethnicities 21 .
Together, these studies suggest that dietary fungal intake contributes substantially to the gut mycobiome and that specific dietary nutrients can sustain specific fungal community members (FIG. 1b) . In support of this, a recent study reported that Candida spp. were positively associated with carbohydrates and were negatively associated with saturated fatty acids, whereas Aspergillus spp. were negatively correlated with dietary short-chain fatty acids 14 .
Mucosal immunity to fungi
The immune system has evolved to tolerate fungi and to respond to them upon injury or infection, and the presence of fungi at mammalian barrier surfaces might constantly shape immunity. Mucosal immunity to fungi has generally been explored in the context of fungal infections 8, 35, [66] [67] [68] [69] [70] [71] [72] (FIG. 2a) . However, very little is known about the role of fungi in influencing immunity during the steady state or during dysbiosis (FIG. 2b) . We discuss below the mechanisms of antifungal immunity, using the lower gastrointestinal tract as a model barrier surface where, despite their high abundance, fungi rarely cause infection but fungal dysbiosis occurs frequently 16, 17, [21] [22] [23] [24] .
The role of cell-mediated immunity
The cell types that are involved in innate and adaptive immune responses to fungi during infection have been well characterized for several barrier surfaces, such as the oral mucosa, the lungs, the vaginal mucosa and the skin 66, 68, 69, [72] [73] [74] [75] [76] (FIG. 2a) 66, 68, 69, [72] [73] [74] [75] [76] [77] [78] . The activation of specific cell types or cell-cell crosstalk is further dependent on the specific barrier surface that is affected by the fungal infection (FIG. 2a) . Whereas some fungi, such as Candida spp., are widely present and can infect several barrier sites, the distribution of other fungi is tissue-dependent 29 . As a central hub of mucosal immunity, the gastrointestinal tract is naturally equipped with cellular machinery to recognize and to interact with the microbiota 79 . The intestine harbours several subsets of phagocytes, which are known to respond to bacterial infections or to fluctuations in the bacterial communities 79 . Although phagocytic cell populations probably sense mycobiota in the intestine, their role during fungal dysbiosis remains unknown.
In addition to cellular innate and adaptive immunity, humoral immune mechanisms such as the complement system and antifungal antibodies have an important role in antifungal immunity 80 and might be involved in shaping the mycobiota at the mucosal surfaces. Innate immune cells are further equipped with a range of receptors to sense and to interact with fungi 5, 29 . 
Figure 2 | Examples of mucosal immune responses to fungal infection and dysbiosis.
The host barrier surfaces are inhabited by mycobiota. Sites such as the skin, lung, oral cavity and the vagina are prone to fungal infections and fungal dysbiosis when host immunity is compromised, whereas the gastrointestinal tract is resistant to fungal infections but susceptible to fungal dysbiosis. Host mucosal immunity has evolved to distinguish fungal infections from fungal dysbiosis. a | Fungal infection leads to breaches in epithelial surfaces, which in turn leads to the rapid infiltration of neutrophils and monocytes at the site of infection. The production of cytokines and chemokines by epithelial and innate immune cells leads to further recruitment of immune cells such as monocytes, neutrophils and different T cell subsets. Resident phagocytes such as macrophages and dendritic cells (DCs) recognize and process fungal antigens and promote fungal-specific T cell responses and polarization. Group 3 innate lymphoid cells (ILC3s) can respond directly to fungi or to the inflammatory environment by producing IL-22 and IL-17. Neutrophils infiltrate and facilitate rapid fungal killing by producing reactive oxygen species (ROS). Epithelial cells produce antimicrobial peptides (AMPs) that directly affect fungal survival. Site-dependent features define mucosal immunity upon fungal infection at different barrier surfaces. b | By contrast, fungal dysbiosis is characterized by alterations in the mycobiota that might be both the cause and the consequence of changes in the tissue environment or in the intestinal lumen. Fungal dysbiosis can influence both local and systemic immunity through several mechanisms, including the modulation of the cytokine milieu, the activation of different cell types and the release of metabolites. Fungal dysbiosis in the gut can influence immunity at distant sites, such as the lung, and can contribute to allergy. Intestinal inflammation and breaches of the intestinal epithelial barrier caused by non-fungal triggers can lead to direct exposure to fungal antigens derived from the intestinal lumen and to the development of systemic IgG and IgA anti-Saccharomyces cerevisiae antibodies (ASCAs). Mucosal immunity to gut fungi during dysbiosis is poorly explored and only a few molecules have been studied in this context. At the barrier surfaces, fungi and bacteria can affect each other; thus, microbiota dysbiosis is probably a collective feature of the complex crosstalk between the fungal and bacterial microbiota and the host. CCR2, CC-chemokine receptor 2; CXCL2, CXC-chemokine ligand 2; IDO1, indoleamine 2,3-dioxygenase 1; IFNγ, interferon-γ; iT reg , induced T regulatory; NK, natural killer; PGE2, prostaglandin E2; TNF, tumour necrosis factor; T H , T helper. 
Chromoblastomycosis
A chronic localized infection of the skin and subcutaneous tissue caused by pigmented fungi that contain sclerotic bodies.
The role of C-type lectin receptors
Genetic evidence and experimental studies have underlined a central role for C-type lectin receptors (CLRs) in antifungal immunity, whereas Toll-like receptors (TLRs) and NOD-like receptors (NLRs) mostly have a secondary role 5, 81 . CLRs, such as dectin 1, dectin 2, dectin 3, macrophage-inducible C-type lectin (MINCLE; also known as CLEC4E) and the mannose receptor, recognize several molecules that are present in the fungal cell wall 5, 81 . Spleen tyrosine kinase (SYK) is the primary signal transduction molecule that is used by several of these receptors, and its activation requires an immunoreceptor tyrosine-based activation motif (ITAM) or ITAM-like motif present within the receptor tail (in the case of dectin 1) or within an associated Fc receptor common γ-chain (FcRγ) adaptor molecule (in the case of dectin 2, dectin 3 and MINCLE) 5, 80, 81 . Upon receptor engagement, ITAM motifs are phosphorylated by SRC family kinases, leading to the recruitment and phosphorylation of SYK and to the activation of a downstream signalling cascade, including phospholipase Cγ2 (PLCγ2), protein kinase Cδ (PKCδ), the caspase recruitment domain-containing protein 9 (CARD9)-BCL-10-mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) complex and inhibitor of κB (IκB) kinase (FIG. 3) . The mannose receptor is an exception and does not activate this pathway 5, 81 .
The role of dectin 1. A receptor for fungal β-glucans, dectin 1 has been studied widely as a crucial receptor for phagocytosis and killing of fungi and the cytokine response to them 82 . Mouse studies have revealed a protective role for dectin 1 in systemic candidiasis 82 and in the control of fungi at several mucosal surfaces, such as the skin 69 , the oral mucosa 67 and the lungs 72 . The role of dectin 1 in protection against Candida spp. infection seems to depend on the specific fungal strain 83 , suggesting that some fungi can mask their cell wall β-glucans and can thus escape recognition. In humans, a mutation in CLEC7A, the gene encoding dectin 1, leads to low dectin 1 expression and impaired cytokine production upon fungal re-stimulation 70 . As a result, patients carrying this mutation often suffer from recurrent vulvovaginal infections and onychomycosis, partly owing to defective IL-17 production in response to fungi 70 . Dectin 1 might also control antifungal immunity during fungal dysbiosis. We have shown that dectin 1-deficient mice developed more severe colitis than wildtype mice, which was accompanied by mycobiota changes and the overgrowth of opportunistic species from genera such as Candida and Trichosporon
16
. This phenotype was dependent on the inability of Clec7a −/− mice to control Candida spp. during intestinal inflammation, and treatment with the antifungal drug fluconazole ameliorated colitis 16, 84 . In situ examination of mouse colons revealed the absence of hyphal growth in the lower gastrointestinal tract during Candida tropicalis colonization of wild-type mice and mice with defects in antifungal immunity 16 (I.L. and I.D.I., unpublished observations). By contrast, hyphal growth is commonly observed during Candida spp. infections at other mucosal sites 66, 69 , and factors involved in hyphal elongation or yeast-to-hypha transition have been shown to aid either fungal invasion (which is mediated by extent of cell elongation 1 (ECE1)) 85 or commensalism (which is mediated by enhanced filamentous growth protein 1 (Efg1)) 86 . This suggests that colitis in Clec7a −/− mice is not aggravated by a typical fungal infection, but that other aspects of host-fungal interactions that affect the mycobiota might be involved. Consistent with results from these mouse models, patients carrying a two-marker CLEC7A haplotype develop severe refractory ulcerative colitis, which supports a possible role for dectin 1 in the severity 16 of, but not the susceptibility to, intestinal disease 87 . Furthermore, dectin 1 deficiency is also associated with increased colonization of the gut by Candida spp. and the development of graft-versus-host disease in patients who have received transplants 88, 89 . Together, these studies suggest that impaired antifungal immunity, Candida spp. overgrowth and fungal dysbiosis might be involved in several intestinal diseases.
The role of dectin 2. Dectin 2 (encoded by Clec6a) has been implicated in the induction of T helper 17 (T H 17) responses and protection from systemic candidiasis 90 ; however, its role in mucosal immunity is less wellexplored. Dectin 2-mediated immunity might be important for the generation of fungi-specific T H 17 responses to Fonsecaea pedrosoi and the resolution of skin infections in a mouse model of chromoblastomycosis 91 . Immunity to the skin commensal Malassezia spp. is also partially controlled by dectin 2 (REF. 92 ). In the lung, dectin 2 might be involved in the recognition of fungal and mite allergens 93 , but Clec6a-knockout mice do not develop more severe lung inflammation than wild-type mice upon infection with fungi such as Cryptococcus neoformans 94 . The role of dectin 2 in human antifungal mucosal defence is even less clear. A recent study described a polymorphism in CLEC6A that is associated with increased susceptibility to pulmonary cryptococcosis 95 . However, it is uncertain whether dectin 2 is directly responsible for this phenotype.
The role of other CLRs. Other CLRs, such as MINCLE and dectin 3, which induce SYK-CARD9-BCL-10-MALT1-dependent signalling, are also involved in mucosal immunity. Dectin 3 induces the expression of MINCLE upon specific stimulation 96 and forms heterodimers with dectin 2 to induce signalling, presumably through FcRγ coupling 97 (FIG. 3) , suggesting that these receptors are expressed in an interdependent manner. Dectin 3-and MINCLE-deficient mice are both susceptible to Candida spp. systemic infections 81, 90, 97 ; however, it is less clear whether these receptors are directly involved in mucosal immunity to fungi. MINCLE, for example, can recognize a lipophilic component of Malassezia spp. cell wall in vitro 92 , but whether such recognition of commensal Malassezia spp. occurs in the skin has not been determined.
Dectin 3, which is encoded by Clec4d, has recently been shown to control intestinal inflammation in mice.
Clec4d
−/− mice developed more severe colitis than wildtype mice, which was associated with an increased C. tropicalis burden and was efficiently treated with 
Deep-seated dermatophytosis
A fungal infection of deep keratinized tissue (including skin, hair and claws).
fluconazole 98 . Decreased numbers of T H 17 cells, impaired phagocytosis by dectin 3-deficient macrophages and a defective intestinal epithelial cell barrier in these mice can be partly responsible for C. tropicalis overgrowth. However, the mechanisms behind increased susceptibility to colitis remain unclear, as levels of several pro-inflammatory cytokines (including tumour necrosis factor) were reduced in the colons of Clec4d −/− mice 98 . Although the structure of the microbiota was not assessed in this study, augmented fungal burden and the increased relative abundance of C. tropicalis in the intestines of Clec4d −/− mice indicate changes to the fungal community. Finally, the relevance of dectin 3 to human intestinal disease remains uncertain owing to a lack of reports on the genetic associations between CLEC4D polymorphisms and IBD.
The role of CARD9 CARD9 occupies a key position downstream of several antifungal receptors, such as the CLRs 81 (FIG. 3) . As such, CARD9 is crucial for the induction of cytokine production and the triggering of cellular immunity to fungi at several mucosal sites 8, 71, 99, 100 . Thus, biallelic mutations in CARD9 have important consequences for the control of mucosal and systemic fungal infections 8, 71, 101 . Although CARD9 might be involved in signalling through receptors that sense stimuli other than fungi, mice and humans that are deficient in CARD9 seem to be specifically susceptible to fungal infections 71, [99] [100] [101] . CARD9-deficient patients often develop chronic mucocutaneous candidiasis that is characterized by persistent and recurrent Candida spp. infections of the mouth, skin, vagina and other mucosal surfaces 8, 71 . CARD9 mutations can also lead to severe onycho mycosis, phaeohyphomycosis and deep-seated dermatophytosis, affecting deeper subcutaneous tissue 8, 102 . Fungal infections in these patients are caused by Trichophyton spp. and Phialophora spp. and can expand to affect the lymph nodes and bones 8, 102, 103 . These rare but severe effects of CARD9 deficiency suggest a central role for this adaptor protein in controlling mucosal and systemic immunity to fungal infections in humans.
In addition, CARD9 has been implicated in IBD. A nonsynonymous single nucleotide polymorphism in CARD9 has been detected with high frequency in both Caucasian (at a frequency of 53%) and African (at a frequency of 25%) populations 104, 105 . This poly morphism is strongly associated with the risk of developing Crohn's disease and ulcerative colitis 106 . Using experimental models of colitis, it was shown that CARD9 signalling can be protective against fungi that encounter the intestinal mucosa during intestinal barrier damage 107 .
Card9
−/− mice had increased antifungal antibodies in serum, and colitis could be partially ameliorated by antifungal treatment, suggesting fungal involvement in the observed phenotype 107 . Furthermore, both the fungal and the bacterial gut communities in Card9 −/− mice were altered 108 . Interestingly, Candida spp. and Aspergillus spp. were barely detectible in Card9 −/− mice, whereas the Sporobolomyces genus was the most prevalent group of fungi 108 , suggesting that C. tropicalis, which expands in dectin 1-and dectin 3-deficient animals 16, 98 , was not the main driver of dysbiosis during CARD9 deficiency. Consistently, human mycobiota studies failed to establish a positive correlation between CARD9 polymorphism and Candida spp. overgrowth in patients with IBD 17 . Finally, apart from the the CARD9 polymorphism reported above 104, 105 , no other CARD9 deficiencies in humans have been associated with a predisposition to IBD.
Although some CARD9 mutations are accompanied by a defect in the production of IL-17 (REF. 71 ), other mutations do not affect IL-17-mediated immunity 109 . Mechanistic studies in mice have demonstrated that a subtle tuning and timing of the CLRs-CARD9-IL-17-mediated response to fungal infections might be taking place 74, 100 . Although CARD9 has a clear role in adaptive T H 17 cell responses to oral C. albicans infection, CLRs trigger phagocytosis and respiratory burst (production of reactive oxygen species (ROS)) through the SYK-dependent activation of phospholipase Cγ2 (PLCγ2), which, in turn, activates NADPH phagocyte oxidase. Engagement of protein kinase Cδ (PKCδ) followed by activation of the CARD9-BCL-10-MALT1 complex leads to nuclear factor-κB (NF-κB) activation, caspase 1 activity and the production of cytokines and other mediators that are crucial for host defence. Dectin-SYK induction also promotes IRF5-dependent interferon-β (IFNβ) production. CD23 is a newly identified CLR that is upregulated upon dectin 1 activation and that leads to the production of ROS. The signalling events downstream of CD23 and the mannose receptor (MR) remain unknown (indicated by a question mark). ASC, apoptosis-associated speck-like protein containing a CARD; CARD9, caspase recruitment domain-containing protein 9; COX2, cyclooxygenase 2; FcRγ, Fc receptor common γ-chain; IRF5, interferon-regulatory factor 5; MALT1, mucosa-associated lymphoid tissue lymphoma translocation protein 1; NFAT, nuclear factor of activated T cells; NLRP3, NOD, LRR and Pyrin domain-containing protein 3; PGE2, prostaglandin E2; TNF, tumour necrosis factor. it was not required for IL-17-dependent innate immunity in this model 100 . In addition, a role of CARD9 in the late stages of mucosal immunity to fungi has been described during Aspergillus fumigatus lung infection 74 . Of note, CARD9 has a redundant role in the induction of T H 17-mediated immunity during systemic infection with other Candida species, such as C. tropicalis 110 . Whether CARD9 can influence T H 17 cell responses during mucosal infection with other non-Candida opportunistic fungi remains to be elucidated.
The role of IL-17 and IL-22
Although more studies are needed to define CARD9-dependent and CARD9-independent regulation of mucosal responses to fungi that are mediated by IL-17, the role of this cytokine during mucosal fungal infections has been determined by multiple human genetic studies and mouse experimental studies, which have been summarized in several recent reviews 80, 81, 111 . Despite the excellent body of experimental work, it is still unclear whether the IL-17 pathway has an effect on commensal fungal communities. A proof-of-concept clinical study exploring IL-17A blockade with secukinumab in patients with Crohn's disease identified an unexpectedly higher rate of fungal infections among the treated individuals 112 . This adverse outcome correlated with augmented intestinal pathology and suggests a possible role of IL-17 in controlling fungal communities; IL-17 can mediate the production of antimicrobial peptides (AMPs) by epithelial cells, which has been shown to clear Candida spp. infection in the oral mucosa 78 . Similar to IL-17, IL-22 acts on epithelial cells as a potent inducer of AMPs and is protective against mucosal Candida spp. and Aspergillus spp. infections 66, 68, 72, 73 . These barrierenhancing properties might explain the indispensable role of IL-17 and IL-22 in the protection against fungal infection at the mucosal surfaces and provide a strong rationale for exploring the role of these pathways in relation to fungal communities in the gut.
Other contributors
Several other molecules, including inflammasome proteins such as NLRP3 and NLRC4, which activate caspase 1 and can process pro-IL-1β into its biologically active form, as well as IL-1β itself, have been explored in the context of mucosal immunity to fungal infections 67, 80, 113 . NOD, LRR and Pyrin domain-containing protein 3 (NLRP3) and NLR family CARD-containing protein 4 (NLRC4) inflammasomes are protective in mouse models of vaginal Candida spp. infection 67, 80, 114 . Furthermore, genetic polymorphisms in NLRP3 are associated with susceptibility to recurrent vulvovaginal candidiasis, increased IL-1β production and hyper-inflammation 115, 116 . Sensing of fungi by NLRP3 inflammasomes seems to be morphotype dependent, with preferential activation by Candida spp. hyphae 80 . However, whether these molecules are involved in the control of the mycobiota during the steady state or upon dysbiosis remains unclear.
Despite our growing knowledge of antifungal immunity and increasing numbers of available antifungal drugs, a rapid rise in fungal infections has prompted the search for novel immunomodulatory strategies to induce immunity to fungi. A recent study has demonstrated that the inhibition of JUN N-terminal kinase 1 (JNK1; also known as MAPK8) promotes the expression of CD23 (a recently discovered CLR), the production of nitric oxide, and a potent antifungal effect both in vitro and in vivo 117 . The E3 ubiquitin ligase casitas B-lineage lymphoma-b (CBLB), which ubiquitylates SYK, was shown to regulate antifungal immune responses downstream of dectin 1 and dectin 2 (REFS 118, 119) (FIG. 3) . Genetic deletion or peptide-based inhibition of CBLB promoted a strong antifungal response, enhanced fungal killing and protected mice during systemic and cutaneous C. albicans infections 118 . Because of their position downstream of several antifungal receptors, CBLB or JNK1 blockade might be a therapeutic avenue to pursue in individuals that have an increased risk of fungal infections and gastrointestinal complications, such as patients who are immunosuppressed or who are infected with HIV. Finally, several other CLRs, chemokine receptors and pathways have been studied in the context of antifungal immunity; however, their role in mucosal immunity to fungi has not been explored.
Interplay between bacteria and fungi Fungi and bacteria share similar niches on the mucosal surfaces and can undoubtedly influence each other. Interactions between fungi and bacteria can occur directly through physical contact and secreted molecules, or indirectly through the alteration of the host immune response. Several studies have attempted to identify interkingdom and intrakingdom correlations between fungi and bacteria using next-generation sequencing 14, 17, 23 . However, this approach needs to be experimentally validated, as correlations between relative abundances are at high risk of identifying false associations 120 . Both clinical studies 21 and mouse models 13, 54 suggest that fungal colonization is modulated by bacterial communities. Short-term antibiotic treatment is sufficient to promote persistent Candida spp. colonization in the mouse gut 13, 54 , with immunological effects at distant sites such as the lung 54, 55 . Although antibiotic treatment rarely promotes the outgrowth of Candida spp. in the oral mucosa 121 , antibiotic-induced vaginal candidiasis is relatively common, suggesting a mucosal site-specific nature of bacterial-fungal interplay. Lactobacilli-induced reduction of pH or the production of a bacteriocin-like compound can inhibit the growth of Candida spp. and are both essential barriers to the colonization of the vaginal mucosa by several fungal species 31, 122 . In addition to lactobacilli, other bacterial species, including Pseudomonas and Burkholderia, as well as bacterial metabolites such as butyrate, can inhibit Candida yeast-to-hypha transitiona process required for the formation of resistant biofilms of fungi and bacteria 123, 124 . However, fungal communities can adapt to the selective pressure exerted by the host and their bacterial neighbours. Analysis of the relatively stable fungal communities in the cystic fibrosis lung, suggests that Candida spp. clones were resistant to the filamentation-repressive effects of Pseudomonas aeruginosa through a mutation in the repressive gene NRG1 (REF. 51 ). Although the formation of biofilms might contribute to the morbidity of both oral and vaginal candidiasis 32, 124 , such biofilms have not been detected in the gut 16, 125 , which is probably owing to the inability of Candida to switch to hyphal growth in this environment. According to a recent study, C. albicans adopts a third GUT (gastrointestinally induced transition) morphology in the intestines that cannot induce systemic disease and that is metabolically accustomed to the intestinal environment 125 . In addition to Candida spp., other fungal species can compete for establishment in an environmental niche. Compounds that are secreted by Pichia spp. can inhibit the in vitro growth of Candida spp., Aspergillus spp. and Fusarium spp., the formation of biofilms by Candida spp., and can reduce fungal burden in a mouse model of oral candidiasis 32 . Similarly, bacteria can indirectly affect fungal colonization through the modulation of the host immune response. For example, in mice, Bacteroides thetaiotaomicron prevents C. albicans colonization of the gut via the HIF1α-mediated production of the antimicrobial peptide CRAMP 126 . The host immune response to fungi might, in turn, indirectly influence bacteria in the gut. A recent study demonstrated that, in the absence of commensal Candida spp., Clec7a −/− mice are protected from colitis through a mechanism that involves the intestinal bacteria 84 . The authors found that, in the absence of Candida spp., antimicrobial peptides targeting Gram-positive bacteria were reduced in the colons of Clec7a −/− mice, leading to an increase in commensal Lactobacillus murinus that induced regulatory T cell expansion and protection from colitis. However, upon colonization with C. tropicalis, this potentially beneficial effect was lost and Clec7a −/− mice developed more severe intestinal inflammation 84 . Similarly, Card9 −/− mice that are susceptible to fungi 99, 107 also carry altered populations of tryptophan-metabolizing bacteria, including reduced levels of lactobacilli 108 . This correlated with decreased levels of aryl hydrocarbon receptor (AHR) ligands and defective Il22, Reg3g and Reg3b expression in the colons of Card9 −/− mice that could be rescued by supplementation with lactobacilli 108 . The protective role of lactobacilli through the production of AHR ligands and the stimulation of IL-22 release by ILCs has been previously described as a mechanism that promotes Candida spp. colonization resistance in the stomach 127 . Whether fungal and bacterial communities influence each other during these cases of apparent inter kingdom dysbiosis in a genetically susceptible host remains unclear. Nevertheless, such studies suggest a more complex microbial interkingdom relationship and possibly a dual role for antifungal immunity pathways in the control of bacterial and fungal populations in the gut.
Finally, the specific disruption of the healthy gut fungal community can also have an adverse effect on host health. We and others 24, 55 have recently demonstrated that prolonged antifungal treatment of healthy wild-type mice exacerbated immune-mediated disease in several experimental models of colitis and lung allergy, leading to the expansion of neutrophils, monocytes, T H 1 cells and T H 17 cells (which was shown in a colitis model), or eosinophils, T H 2 cells and IgE-producing B cells (which was shown in a lung allergy model (FIG. 2b) ) 24, 55 . Analysis of the mycobiota in mice treated with fluconazole and amphotericin B revealed dramatic changes in the composition and diversity of the gut mycobiota, suggesting the induction of gut fungal community dysbiosis 24 . Oral supplementation with Aspergillus amstelodami, Epicoccum nigrum and Wallemia sebi, which expanded during fungal dysbiosis, was sufficient to recapitulate the detrimental effects of antifungal drugs on inflammatory disease. In addition to the mycobiota, drug-induced fungal dysbiosis may affect bacterial community structure and genera, such as Bacteroides, Clostridium and Lactobacillus, which are also decreased during fungal dysbiosis 25 .
Concluding remarks
An increasing number of studies are detailing the complexity of antifungal immune responses, but most evidence focuses on fungal infections. Increasing evidence indicates that human barrier surfaces harbour diverse communities of fungi that cohabit with the host throughout its life. Although opportunistic fungi within those communities can cause pathologies in susceptible individuals, most host-fungal interactions at the body surfaces are non-infectious. This raises several questions: do commensal fungi, similar to bacteria, contribute to shaping and maintaining immune homeo stasis? Which pathways and intercellular networks are involved in sensing commensal fungi during the steady state? The characterization of immune responses in the presence of dysbiotic and steady-state fungal communities might provide key answers. Future studies on the crosstalk between the mycobiota, fungal metabolites, epithelium and mucosa-resident immune cells will propel the field towards understanding how the mycobiota interacts with host immunity at barrier surfaces. Understanding the mechanisms behind fungal dysbiosis might provide diagnostic and therapeutic targets by identifying fungi that could be or that should not be targeted during inflammatory conditions.
Interkingdom microbiome interactions involving fungi can also indirectly modulate immunity by affecting microbiome function and metabolism. The application of metagenomics, metatranscriptomics and meta bolomics holds promise for identifying the mediators of interkingdom interactions; however, the use of experimental approaches to validate the mediators remains crucial. The fast-growing field of antifungal immunity has entered a new age in which a focus on complex microbial communities rather than a single fungal species will shed light on the role of the mycobiota in homeo stasis and inflammation. Collectively, an increasing body of evidence suggests crosstalk between gut fungi, bacteria and the host mucosal immunity. Disruption of this network can contribute to interkingdom microbial community alterations with detrimental consequences to the host and thus positions fungi in the crossfire between mucosal immunity and commensal bacteria.
